Alexey Danilov, MD

Conference Coverage

Prognostic Value of Undetectable MRD Status Among Patients With Follicular Lymphoma Post-Initial Treatment

01/10/2024

At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Exciting Developments and Novel Targets in Chronic Lymphocytic Leukemia Treatment

10/21/2024

Alexey Danilov , MD;

Alexey Danilov, MD, reviews the latest exciting developments in the chronic lymphocytic leukemia clinical research landscape, highlighting BTK and BCL2 inhibitors as well as BTK degraders.

Alexey Danilov, MD, reviews the...

10/21/2024

Oncology

Conference Coverage

Selecting Optimal Frontline Therapies for Treating Patients With CLL

10/21/2024

Alexey Danilov , MD;

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.

At the 2024 Lymphoma, Leukemia &...

10/21/2024

Oncology